Literature DB >> 3872263

Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine.

K L Cates, K H Marsh, D M Granoff.   

Abstract

We measured the uptake of radiolabeled Haemophilus influenzae type b by human polymorphonuclear leukocytes. Haemophilus influenzae type b strains were preopsonized in individual sera from six adults immunized with type b polysaccharide vaccine (PRP) or six adults immunized with PRP covalently coupled to diphtheria toxoid (PRP-D vaccine). Serum was heat inactivated before use, and exogenous human complement was added. Of the 12 subjects, 3 had high levels of opsonic activity (greater than 40% of immune control) in their preimmunization serum. This activity did not correlate with the concentrations of anti-PRP antibody and was unaffected by absorption of anti-PRP antibody. At 1 month after vaccination, the serum of PRP-D subjects had higher opsonic activity than that from subjects who received PRP (5% serum, mean PRP-D = 86%, mean PRP = 53%, P = 0.001). After 12 months, both groups had higher serum opsonic activity than before immunization (P less than 0.02), but there was no difference between the two groups (mean PRP-D = 48%, mean PRP = 51%). In postimmunization serum, opsonic activity induced by PRP-D or PRP vaccines correlated directly with anti-PRP antibody concentrations as measured by a radioantigen binding assay. We conclude that both vaccines induce opsonic activity, opsonic activity induced by immunization of adults correlates well with the concentration of anti-PRP antibody achieved, and in preimmune sera with low concentrations of anti-PRP antibody, factors other than anti-PRP antibody contribute to opsonic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872263      PMCID: PMC261933          DOI: 10.1128/iai.48.1.183-189.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

2.  Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children.

Authors:  G S Giebink; J E Foker; Y Kim; G Schiffman
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

3.  Prospective evaluation of treatment of Hemophilus influenzae meningitis.

Authors:  R D Feigin; B W Stechenberg; M J Chang; L M Dunkle; M L Wong; H Palkes; P R Dodge; H Davis
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

4.  The Protective or Curative Element in Type B H. influenzae Rabbit Serum.

Authors:  H E Alexander; M Heidelberger; G Leidy
Journal:  Yale J Biol Med       Date:  1944-05

5.  The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia.

Authors:  P F Weller; A L Smith; P Anderson; D H Smith
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

6.  Immunogenicity of Haemophilus influenzae type b polysaccharide--diphtheria toxoid conjugate vaccine in adults.

Authors:  D M Granoff; E G Boies; R S Munson
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

7.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

8.  Detection and quantitation of bacteremia in childhood.

Authors:  M Santosham; E R Moxon
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

9.  Opsonization and phagocytosis of Haemophilus influenzae type B organisms by mouse polymorphonuclear leucocytes and antiribosomal serum.

Authors:  M A Katz; M Solotorovsky; M Lynn
Journal:  Br J Exp Pathol       Date:  1983-06

10.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

View more
  11 in total

1.  Opsonic effect of jacalin and human immunoglobulin A on type II group B streptococci.

Authors:  N R Payne; N F Concepcion; B F Anthony
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.

Authors:  S V Hetherington; C C Patrick
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b.

Authors:  S V Hetherington
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

4.  Effect of complement depletion on anticapsular-antibody-mediated immunity to experimental infection with Haemophilus influenzae type b.

Authors:  J R Schreiber; C J Basker; G R Siber
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 5.  Conjugate vaccines: practice and theory.

Authors:  R S Becker
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide.

Authors:  R D Shahin; J Hamel; M F Leef; B R Brodeur
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b.

Authors:  R S Munson; D M Granoff
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

9.  Human antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae mediate opsonophagocytic activity.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.